Voss Capital, Lp Acquires 30,176 Shares of Rein Therapeutics (NASDAQ:RNTX) Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) major shareholder Voss Capital, Lp purchased 30,176 shares of Rein Therapeutics stock in a transaction dated Friday, October 24th. The shares were purchased at an average cost of $1.39 per share, for a total transaction of $41,944.64. Following the transaction, the insider owned 729,616 shares in the company, valued at approximately $1,014,166.24. This trade represents a 4.31% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Voss Capital, Lp also recently made the following trade(s):

• On Tuesday, October 28th, Voss Capital, Lp bought 178,392 shares of Rein Therapeutics stock. The stock was purchased at an average cost of $1.39 per share, for a total transaction of $247,964.88.
• On Monday, October 27th, Voss Capital, Lp bought 97,482 shares of Rein Therapeutics stock. The stock was purchased at an average cost of $1.37 per share, for a total transaction of $133,550.34.

Rein Therapeutics Stock Up 17.4%

Shares of NASDAQ RNTX opened at $1.55 on Thursday. The firm has a market cap of $36.13 million, a price-to-earnings ratio of -0.58 and a beta of 1.14. Rein Therapeutics Inc. has a 52-week low of $1.04 and a 52-week high of $4.16. The business’s 50 day moving average is $1.25 and its two-hundred day moving average is $1.50.

Rein Therapeutics (NASDAQ:RNTX) last announced its earnings results on Thursday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Analysts anticipate that Rein Therapeutics Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on RNTX. Brookline Capital Management downgraded shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 19th. HC Wainwright began coverage on shares of Rein Therapeutics in a research note on Monday, September 22nd. They issued a “buy” rating and a $10.00 price target for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Hedge Funds Weigh In On Rein Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Gleason Group Inc. acquired a new position in shares of Rein Therapeutics during the third quarter worth $26,000. Blair William & Co. IL acquired a new position in shares of Rein Therapeutics during the second quarter worth $33,000. Meridian Wealth Advisors LLC acquired a new position in shares of Rein Therapeutics during the second quarter worth $40,000. Exencial Wealth Advisors LLC acquired a new position in shares of Rein Therapeutics during the second quarter worth $43,000. Finally, Chicago Partners Investment Group LLC acquired a new position in shares of Rein Therapeutics during the second quarter worth $64,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.